Q0155 — Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0161 — Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0166 — Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
Q0167 — Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0169 — Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0173 — Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0174 — Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0175 — Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0177 — Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0180 — Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
Q0181 — Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0224 — Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
Q0235 — Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, not otherwise classified, 1 mg
Q0237 — Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
Q0249 — Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
Q0477 — Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0478 — Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
Q0479 — Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0480 — Driver for use with pneumatic ventricular assist device, replacement only
Q0481 — Microprocessor control unit for use with electric ventricular assist device, replacement only
Q0482 — Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Q0483 — Monitor/display module for use with electric ventricular assist device, replacement only
Q0484 — Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0485 — Monitor control cable for use with electric ventricular assist device, replacement only
Q0486 — Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only
Q0487 — Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only
Q0488 — Power pack base for use with electric ventricular assist device, replacement only
Q0489 — Power pack base for use with electric/pneumatic ventricular assist device, replacement only
Q0490 — Emergency power source for use with electric ventricular assist device, replacement only
Q0491 — Emergency power source for use with electric/pneumatic ventricular assist device, replacement only
Q0492 — Emergency power supply cable for use with electric ventricular assist device, replacement only
Q0493 — Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only
Q0494 — Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0495 — Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0496 — Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0497 — Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0498 — Holster for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0499 — Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only
Q0500 — Filters for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0501 — Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0502 — Mobility cart for pneumatic ventricular assist device, replacement only
Q0503 — Battery for pneumatic ventricular assist device, replacement only, each
Q0504 — Power adapter for pneumatic ventricular assist device, replacement only, vehicle type
Q0506 — Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0507 — Miscellaneous supply or accessory for use with an external ventricular assist device
Q0508 — Miscellaneous supply or accessory for use with an implanted ventricular assist device
Q0509 — Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a
Q0510 — Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
Q0511 — Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
Q0512 — Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
Q0513 — Pharmacy dispensing fee for inhalation drug(s); per 30 days
Q0514 — Pharmacy dispensing fee for inhalation drug(s); per 90 days
Q2034 — Influenza virus vaccine, split virus, for intramuscular use (agriflu)
Q2035 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
Q2036 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
Q2037 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
Q2038 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
Q2039 — Influenza virus vaccine, not otherwise specified
Q2041 — Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2042 — Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2043 — Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
Q2052 — Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG)
Q2053 — Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2054 — Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2055 — Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2056 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2057 — Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2058 — Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Q3001 — Radioelements for brachytherapy, any type, each